The traditional management paradigm for pediatric germ cell tumors combines surgical resection with chemotherapy, a regimen that, while broadly effective, does not uniformly benefit all tumor subtypes. Moreover, chemotherapy-induced toxicity often results in debilitating side effects, underscoring the urgent need for more nuanced treatment strategies. Addressing this gap, researchers at Hospital de Amor embarked on an ambitious project to characterize the “immune environment” of pediatric GCTs. This approach focuses on decoding how immune cells within the tumor microenvironment interact with malignant cells, potentially influencing tumor behavior and response to treatment.

Mariana Tomazini, a leading researcher and study advisor at CPOM, contextualizes the rarity and complexity of these tumors. Pediatric GCTs manifest in multiple anatomical sites—including gonadal and extragonadal locations such as the ovaries, testicles, central nervous system, and retroperitoneum—and exhibit several histological subtypes. These histologies represent distinct cellular landscapes and growth paradigms, essentially serving as a “biological signature” that can inform clinical decision-making. Tomazini highlights that understanding these signatures is paramount in crafting personalized treatment protocols.

The study, financially supported by the São Paulo Research Foundation (FAPESP) under grants 19/07502-8 and 23/07073-5, was executed as part of the master’s research project led by Lenilson Silva. The team meticulously analyzed tissue samples sourced from 17 pediatric patients diagnosed with germ cell tumors between 2000 and 2021, encompassing ovarian, testicular, and central nervous system specimens. In parallel, normal non-tumorous tissues were used as controls to establish baseline immune parameters. Their findings were recently published in the esteemed journal Frontiers in Immunology, marking a significant contribution to the field of pediatric oncology.

Employing advanced molecular profiling techniques, the researchers assessed the expression of approximately 800 genes associated with immune system function. This high-resolution analysis enabled them to map the diversity and density of immune cell infiltrates, including key subsets such as T lymphocytes, within tumor microenvironments. To draw meaningful comparisons, gene expression patterns from pediatric tumors were juxtaposed with publicly available genomic data from adult germ cell tumors, revealing age-specific immunological landscapes that had previously gone unexplored.

One of the pivotal discoveries of the research lies in the demonstration that each histological subtype of pediatric GCT possesses a discrete and unique immune profile. This finding is instrumental in decoding the mechanisms behind varying clinical behaviors and therapeutic responses observed in these tumors. For instance, dysgerminomas—primarily ovarian tumors—were found to harbor an immunologically “active” milieu characterized by a robust infiltration of cytotoxic CD8+ T cells. These immune effector cells are known for their capacity to identify and destroy malignant cells, potentially accounting for the generally favorable prognosis associated with this subtype.

Intriguingly, dysgerminomas also exhibit elevated levels of immune checkpoint molecules such as CTLA-4, TIGIT, and IDO1. These proteins are critical regulators that can suppress immune activation, allowing tumors to evade immune surveillance. This characteristic suggests that dysgerminomas could be susceptible to immune checkpoint blockade therapies, a class of immunotherapeutics that has transformed treatment paradigms in adult malignancies like melanoma and non-small cell lung cancer. Hence, the study underscores the potential of repurposing such therapies for pediatric patients with this tumor subtype.

Conversely, a starkly different immunological landscape was observed in endodermal sinus tumors, also known as yolk sac tumors (YSTs). These tumors exhibited an immunosuppressive microenvironment marked by exhausted T lymphocytes, indicative of impaired antitumor immune responses. Moreover, the presence of immunoevasive molecules such as CD24 and PVR was markedly increased. CD24, in particular, is implicated in promoting immune evasion and chemotherapy resistance, correlating with the aggressive nature and poorer prognosis of YSTs. This nuanced understanding of immune dysfunction opens avenues for targeting these molecules to restore immune competency and therapeutic sensitivity.

Embryonic carcinomas also demonstrated elevated CD24 expression, reinforcing its role as a pivotal marker of tumor aggressiveness and immune escape. Given that prior studies have shown that blocking CD24 can resensitize tumors to chemotherapy, these findings suggest that CD24 inhibition might be a promising adjunct in treating these tumors. Such targeted immunomodulation could mitigate the toxicities associated with conventional treatments by refining therapeutic precision.

Interestingly, mixed germ cell tumors originating in the central nervous system revealed fewer significant immune alterations, a phenomenon that may reflect their cellular heterogeneity or the limitations posed by smaller sample sizes. This observation signals the need for expanded studies with more extensive cohorts to fully elucidate the immune characteristics of these rarer subtypes and ensure comprehensive therapeutic strategies.

The implications of these findings extend beyond academic interest; they herald a paradigm shift toward individualized medicine in pediatric oncology. Recognizing that each tumor subtype maintains a distinct immunological fingerprint validates the concept that uniform treatment regimens are suboptimal. Tailored therapeutic approaches, potentially incorporating immunotherapy modalities, could maximize efficacy while minimizing long-term sequelae. This is particularly critical in pediatric populations where treatment-related morbidities can severely impact quality of life decades after remission.

Despite the invaluable contributions of this study, the authors acknowledge its limitations, primarily the modest sample size inherent in rare pediatric cancers and the absence of representation for all histological variants. Nevertheless, as a pioneering effort, it lays a robust foundation for multicenter collaborations aiming to validate these biomarkers across larger populations. The ultimate goal is to transition from bench to bedside by integrating these immune profiles into clinical trials assessing targeted immunotherapies and improving pediatric treatment outcomes.

Mariana Tomazini emphasizes the overarching ambition of this work: to discover biomarkers that refine diagnostic accuracy and enable the selection of targeted, less toxic therapies. “Understanding the immunological distinctions between tumor subtypes brings us closer to achieving personalized medicine that can provide children with safer and more effective treatment options,” she asserts. The study not only advances scientific knowledge but also embodies hope for a future where pediatric germ cell tumors are tackled with unprecedented precision and compassion.

This research has earned prestigious recognition, securing the award for best paper at the recent Latin American Society of Pediatric Oncology (SLAOP) conference in Colombia. SLAOP’s mission to foster interdisciplinary advances in pediatric oncology and hematology aligns seamlessly with the goals of this study — driving scientific innovation to improve clinical care for young cancer patients globally.

As immuno-oncology continues to reshape cancer treatment in adults, this seminal research marks a critical inflection point for pediatric germ cell tumors. By harnessing the power of immune profiling, scientists are unraveling the complex interplay between cancer and the immune system, opening new frontiers for therapy development. The next chapters in this journey will be written through multicenter trials and clinical applications that translate these molecular insights into tangible benefits for children worldwide.

Subject of Research: Pediatric Germ Cell Tumors and Immune Profiling

Article Title: Immune profiling of pediatric germ cell tumors identifies key cell populations and novel therapeutic targets

News Publication Date: 20-Jun-2025

Web References:

• DOI
• Hospital de Amor – CPOM
• FAPESP Research Grants | FAPESP Scholarship

References:
Silva L, Tomazini M, et al. Immune profiling of pediatric germ cell tumors identifies key cell populations and novel therapeutic targets. Frontiers in Immunology. 2025.

PITTSBURGH, March 19, 2025 – Researchers and pediatric neurosurgeons at the University of Pittsburgh School of Medicine and UPMC Children’s Hospital of Pittsburgh developed a new way to profile brain cancers in children, paving the way for improved diagnostics and treatments.

Today in Science Translational Medicine, researchers describe a diagnostic platform that could classify brain tumors based on the body’s cancer-fighting immune response. This approach, which is complementary to traditional microscopic and genetic cancer cell analyses, establishes an opportunity to tailor cancer therapies to each patient’s unique immune response and harness the success of immunotherapies that revolutionized the treatment of childhood leukemias.

“Understanding how the repertoire of immune cells fits with the diverse landscape of brain cancer types can help us find new therapies in the future,” said lead author Itay Raphael, Ph.D., research assistant professor of neurological surgery at Pitt.

Brain cancer is the second most common cancer in children after leukemia, and it is also the deadliest. This is due to a constellation of factors: Brain tumors are diverse, resistant to treatments and often hard to access surgically. On the other hand, the sharp reduction of deaths from leukemia over the recent decades is due in part to the enormous success of immune-based therapies, which harness the body’s intrinsic protective mechanisms by expanding the pool of cancer-fighting white blood cells called T cells.

T cells are precisely tuned to recognize molecules on the surface of cancer cells – called antigens – and use them as signals to attack and clear out tumor cells while leaving healthy cells intact. When T cells find a target on the tumor cell surface, they become activated and start rapidly doubling their numbers in a process called clonal expansion, aimed to clear the cancer.

Because of how varied brain tumors and their antigens are, understanding the tumor’s molecular composition can help clinicians personalize each patient’s treatment. Similarly, the new study’s complementary approach can help pinpoint the best treatment option by identifying which T cell-surface receptors are most abundant in the environment surrounding the tumor.

“The success of T cell-based therapies for non-brain tumors, including childhood leukemias, suggests tremendous potential for brain cancers,” said senior author Gary Kohanbash, Ph.D., assistant professor of neurological surgery at Pitt. “Having access to an unprecedented dataset of pediatric tumors and new bioinformatic tools allowed us to investigate how T cell immune response and clonal expansion could be used as markers for treatment classification and prognosis independent of other diagnostic tools.”

As part of the study, the researchers profiled nearly 1,000 pediatric brain tumor samples, which were collected through the Children’s Brain Tumor Network (CBTN), a medical research consortium of 35 medical centers across the nation and globally. The study was first to look at the T cell clonal repertoire and expansion in this sample group.

The group observed that very aggressive tumor types are associated with less T cell expansion than less aggressive ones, suggesting that clonality can inform patient outcomes across tumor types. On the other hand, studying T cell response can shed light on which antigens on the surface of cancer cells can be exploited therapeutically, offering avenues for development of cancer-antigen peptide immunotherapy.

“Ultimately, we hope for a future where clonal T cell expansion is incorporated into pediatric cancer diagnosis,” said co-author Ian Pollack, M.D., distinguished professor of neurological surgery at Pitt, and a founding institutional principal investigator of CBTN. “UPMC Children’s Hospital is committed to supporting brain tumor research and developing new life-saving treatments, and we think that this landmark study represents a foundational shift to how the field will be considering pediatric tumors in the future.”

Other authors of the study include Zujian Xiong, Chaim Sneiderman, Rebecca Raphael, M.S., Sydney Jackson, ReidAnn Sever, Sarah Vincze, Baoli Hu, Ph.D., Sameer Agnihotri, Ph.D., Jan Drappatz, M.D., Taylor Abel, M.D., Shikhar Uttam, Ph.D., Michal Nisnboym, M.D., Yael Nechemia-Arbely, Ph.D., Udai Kammula, M.D., Jeremy Rich, M.D., Thomas Pearce, M.D., Ph.D., Maria Chikina, Ph.D., and Dhivyaa Rajasundaram Ph.D., all of Pitt, among others.

Journal

Science Translational Medicine

Funder

NIH/National Institutes of Health,
Botha-Chan Research Fund,
Brain Tumor Funders’ Collaborative,
Ellie Kavalieros DIPG Research Fund,
Office of the Assistant Secretary of Defense for Health Affairs,
UPMC Children’s Hospital Foundation,
Haley Weiss Memorial Fund,
Children’s Brain Tumor Network,
Gift From a Child,
Swifty Foundation

DOI

10.1126/scitranslmed.adp0675

Traditionally, children diagnosed with this condition receive a standardized treatment regimen that includes surgery, chemotherapy, and radiation therapy. However, while some children may respond favorably to these interventions, others face the grim prospects of rapid tumor relapse due to the aggressive nature of their specific cancer subtype. This disparity in treatment response underscores the urgent need for accurate tumor classification methods, allowing for tailored therapeutic strategies that meet individual patient needs.

The researchers, led by Dr. Alberto Delaidelli, a postdoctoral fellow at UBC, in collaboration with esteemed colleagues from BC Cancer and BC Children’s Hospital, have introduced a scientifically rigorous approach that leverages proteomics—an innovative field focused on protein analysis within biological systems. By examining the intricate protein expressions in nearly 400 clinical tumor samples, Dr. Delaidelli’s team was able to pinpoint MYC, a crucial protein that displayed a marked presence in the most aggressive cases of medulloblastoma.

The revelation that MYC-positive tumors are significantly more likely to exhibit resistance to treatment and a higher risk of relapse is critical in shaping future treatment protocols. By integrating immunohistochemistry (IHC)—a widely employed and accessible laboratory technique—the researchers have established a diagnostic test that can be performed rapidly, achieving results within a single day. This is in stark contrast to existing methods reliant on expensive and time-consuming genetic testing, which are often exclusive to specialized laboratories.

What sets this new test apart is not merely its swiftness but also its potential accessibility across global healthcare infrastructures. Dr. Sorensen, a distinguished scientist at BC Cancer and leading figure in this study, emphasizes that this methodology can be executed in standard pathology labs worldwide, making it feasible for hospitals in both developed and developing nations. This democratization of diagnostic capabilities could facilitate timely and appropriate treatment decisions for pediatric patients, ensuring that those in dire need of intensive therapy receive it without delay.

As medulloblastoma continues to be the leading cause of cancer-related mortality in children, this research is particularly timely. In Canada and the United States alone, approximately 500 cases are reported annually. Nevertheless, the landscape of pediatric oncology remains fraught with difficulties, ranging from the complexities of diagnosing various tumor subtypes to the implementation of effective treatment strategies that do not compromise the long-term quality of life for young patients.

The implications of this research extend far beyond immediate clinical applications; it opens avenues for future studies aimed at understanding the molecular mechanisms that drive tumor aggression and resistance. By fostering a deeper understanding of these biological underpinnings, the scientific community can innovate new therapeutic agents designed to target these specific pathways, potentially transforming the prognosis for young patients diagnosed with this formidable disease.

Particularly concerning is the fact that treatments such as radiation, while effective, can yield severe long-term side effects. Children exposed to radiation therapy often grapple with cognitive deficits, developmental delays, and various other challenges as they transition into adulthood. By employing the MYC test to accurately gauge the necessity of radiation in individual cases, medical professionals can mitigate the risk of administering overtreatment, focusing instead on personalized care that prioritizes the child’s well-being and future development.

This research is further bolstered by its collaborative nature, involving experts from multiple Canadian cities and international institutions, including a notable participation from Heidelberg, Germany. Such partnerships reflect a growing trend in scientific research where global networks aim to tackle pressing health issues through shared knowledge and resources, enhancing the capacity for rapid translation of laboratory findings into clinical practice.

In allowing for swift diagnosis and treatment decision-making, the MYC test represents not just a technical advancement, but a paradigm shift in pediatric cancer care—a beacon of hope for families facing the daunting challenges posed by medulloblastoma. Medical professionals are now equipped with the tools necessary to make more informed decisions that align with the unique needs of each patient, fostering a future where personalized medicine becomes the norm rather than the exception.

As this test gains momentum in clinical practice, it is poised to redefine the standards of care in pediatric oncology. With the push for more precise and individualized treatment approaches, and with research continually illuminating new pathways for intervention, the future of pediatric cancer care appears increasingly promising. As families rally behind their young patients, this advancement provides a renewed sense of hope in the fight against one of the most aggressive forms of childhood cancer.

By bridging the gap between groundbreaking research and practical application, the team at UBC not only contributes to the academic body of knowledge surrounding medulloblastoma but also reinforces the importance of translating these discoveries into tangible clinical benefits for patients across the globe. This is a pivotal moment for medical science, where the collaboration of experts results in innovations that hold the potential to save lives and improve the quality of life for generations of children to come.

The ongoing development and validation of this MYC-focused diagnostic tool augur well for the evolution of pediatric oncology, cementing the role of proteomics as a transformative discipline in understanding and combatting cancer. As medical practitioners worldwide adopt these findings, the implications reach far beyond medulloblastoma, resonating throughout the broader landscape of cancer research and treatment.

By fostering collaboration, accelerating research, and prioritizing patient-centric care, the next era of cancer treatment could very well be marked by a commitment to innovation, access, and tailored solutions that recognize and address the complexities of individual cases. The unwavering efforts of researchers and clinicians will ultimately determine the trajectory of pediatric oncology, highlighting the vital intersection of science, compassion, and hope in the quest to conquer cancer.

Subject of Research: Cells
Article Title: High-resolution proteomic analysis of medulloblastoma clinical samples identifies therapy resistant subgroups and MYC immunohistochemistry as a powerful outcome predictor
News Publication Date: March 5, 2025
Web References: Neuro-Oncology
References: DOI – 10.1093/neuonc/noaf046
Image Credits: Not available

Keywords: Brain tumors, Children, Medulloblastoma, Cancer research.